SPRYCEL 10 mg/ml, powder for oral suspension bottle, 120 ml
Active ingredients: Dasatinib, Dasatinib monohydrate
Commercialized according to BDPMDispensing in France: Prescription only
Powder for oral suspensionbottle, 120 mlorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- SPRYCEL 10 mg/mL, poudre pour suspension buvable
- Pharmaceutical form
- poudre pour suspension buvable
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) de 120 ml avec fermeture de sécurité enfant avec seringue(s) pour administration orale avec adaptateur(s) pour flacon
- Marketing authorisation holder
- BRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 10 Dec 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61641704CIP73016026CIP133400930160268Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DASATINIB MONOHYDRATÉpoudre | — | SA |
| DASATINIBpoudre | 10 mg · 1 mL après reconstituion | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.